Changes in Helicobacter pylori status in patients with rheumatoid arthritis under non‐steroidal anti‐inflammatory drugs

References

• Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulcer. Lancet 1984; 1: 1311–5.
   PubMed Web of Science ®Google Scholar
• Roth SH, Bennett RE. Nonsteroidal anti-inflammatory drug gastropathy. Arch Intern Med 1987;147:2093–100.
   PubMedGoogle Scholar
• Graham DY, Smith JL. Gastroduodenal complications of chronic NSAID therapy. Am J Gastroenterol 1988;83:1081–4.
   PubMed Web of Science ®Google Scholar
• Chan FK, Sung JJ, Chung SC, To KF, Yung MY, Leung VK, et al. Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet 1997;350:975–9.
   PubMed Web of Science ®Google Scholar
• Taha AS, Dahill S, Morran C, Hudson N, Hawkey CJ, Lee FD, et al. Neutrophils, Helicobacter pylori, and nonsteroidal antiinflammatory drug ulcers. Gastroenterology 1999;116:254–8.
   PubMed Web of Science ®Google Scholar
• Chan FK, To KF, Wu JC, Yung MY, Leung WK, Kwok T, et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal antiinflammatory drugs: a randomised trial. Lancet 2002;359:9–13.
   PubMed Web of Science ®Google Scholar
• Huang JQ, Srindhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in pepticulcer disease: a meta-analysis. Lancet 2002;359: 14–22.
   Google Scholar
• Loeb DS, Talley NJ, Ahlquist DA, Carpenter HA, Zinsmeister AR. Long-term nonsteroidal anti-inflammatory drug use and gastroduodenal injury. The role of Helicobacter pylori. Gastroenterology 1992;102:1899–905.
   Google Scholar
• Goggin PM, Collins DA, Jazrawi RP, Jackson PA, Corbinshley CM, Bourke BE, et al. Prevalence of Helicobacter pylori infection and its effect on symptoms and non-inflammatory drug induced gastrointestinal damage in patients with rheumatoid arthritis. Gut 1993;34:1677–80.
   PubMed Web of Science ®Google Scholar
• Mizokami Y, Tamura K, Fukuda Y, Yamamoto I, Shimoyama T. Non-steroidal anti-inflammatory drugs associated with gastroduodenal injury and Helicobacter pylori. Eur J Gastroenterol Hepatol 1994;6 Suppl 1:S109–12.
   PubMedGoogle Scholar
• Voutilainen M, Sokka T, Juhola M, Farkkila M, Hannonen P. Nonsteroidal anti-inflammatory drug-associated upper gastrointestinal lesions in rheumatoid arthritis patients. Relationship to gastric histology, Helicobacter pylori infection, and factors for peptic ulcer. Scand J Gastroenterol 1998;33: 811–6.
   PubMedGoogle Scholar
• Ishikawa N, Fuchigami T, Matsumoto T, Kobayashi H, Sakai Y, Tabata T, et al. Helicobacter pylori infection in rheumatoid arthritis: effect of drugs on prevalence and correlation with gastroduodenal lesions. Rheumatology 2002;41:72–7.
   PubMedGoogle Scholar
• Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–24.
   PubMed Web of Science ®Google Scholar
• Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney system. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996;20: 1161–81.
   Google Scholar
• Tabata H, Fuchigami T, Kobayashi H, Sakai Y, Nakanishi M, Tomioka K, et al. Helicobacter pylori and mucosal atrophy in patients with gastric cancer: a special study regarding the methods for detecting Helicobacter pylori. Dig Dis Sci 1999;44: 2027–34.
   PubMedGoogle Scholar
• Hazell SL. Cultural techniques for the growth and isolation of Helicobacter pylori. In: Goodwin CS, Worsley BW, editors. Helicobacter pylori. Biology and clinical practice. Boca Raton: CRS Press; 1993. p. 273–83.
   Google Scholar
• Holton J. The use of culture in the diagnosis of Helicobacter pylori infection. Eur J Gastroenterol Hepatol 1993; 5 Suppl 2: S41–3.
   Google Scholar
• Ritchie DM, Boyle JA, McInnes JM, Jasani MK, Dalakos TG, Grieveson P, et al. Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. Q J Med 1968;37:393–406.
   PubMedGoogle Scholar
• Kobayashi H, Tada S, Fuchigami T, Okuda Y, Takasugi K, Matsumoto T, et al. Secondary amyloidosis in patients with rheumatoid arthritis: diagnostic and prognostic value of gastroduodenal biopsy. Br J Rheumatol 1996;35:44–9.
   PubMedGoogle Scholar
• Nesland AA, Berstad A. Effect of cimetidine in patients with non-ulcer dyspepsia and erosive prepyloric changes. Scand J Gastroenterol 1985;20:629–35.
   PubMed Web of Science ®Google Scholar
• Miwa T, Miyoshi A. Famotidine in the treatment of gastritis. Scand J Gastroenterol 1987;22 Suppl 134:46–50.
   Google Scholar
• Berkowitz JM, Rogenes PR, Sharp JT, Warner CW. Ranitidine protects against gastroduodenal mucosal damage associated with chronic aspirin therapy. Arch Intern Med 1987;147:2137–9.
   PubMedGoogle Scholar
• Labenz J, Blum AL, Bayerdorffer E, Meining A, Stolte M, Borsch G. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology 1997;112:1442–7.
   PubMed Web of Science ®Google Scholar
• Koike T, Ohara S, Sekine H, Iijima K, Kato K, Shimosegawa T, et al. Helicobacter pylori infection inhibits reflux esophagitis by inducing atrophic gastritis. Am J Gastroenterol 1999;94:3468–72.
   PubMed Web of Science ®Google Scholar
• Befrits R, Sjöstedt S, Ödman B, Sorngard H, Lindberg G. Curing Helicobacter pylori infection in patients with duodenal ulcer does not provoke gastroesophageal reflux disease. Helicobacter 2000;5:202–5.
   PubMedGoogle Scholar
• Moayyedi P, Bardhan C, Young L, Dixon MF, Brown L, Axon AT. Helicobacter pylori eradication does not exacerbate reflux symptoms in gastroesophageal reflux disease. Gastroenterology 2001;121:1120–6.
   PubMed Web of Science ®Google Scholar
• Parsonnet J, Blaser MJ, Perez-Perez GI, Hargrett-Bean N, Tauxe RV. Symptoms and risk factors of Helicobacter pylori infection in a cohort of epidemiologists. Gastroenterology 1992;102:41–6.
   Google Scholar
• Kuipers EJ, Pena AS, van Kamp G, Uyterlinde AM, Pals G, Pels NF, et al. Seroconversion for Helicobacter pylori. Lancet 1993; 342:328–31.
   PubMed Web of Science ®Google Scholar
• Cullen DJ, Collins BJ, Christiansen KJ, Epis J, Warren JR, Surveyor I, et al. When is Helicobacter pylori infection acquired? Gut 1993;34:1681–2.
   Google Scholar
• Veldhuyzen van Zanten SJ, Pollak PT, Best LM, Bezanson GS, Marrie T. Increasing prevalence of Helicobacter pylori infection with age: continuous risk of infection in adults rather than cohort effect. J Infect Dis 1994;169:434–7.
   PubMed Web of Science ®Google Scholar
• Niemela S, Karttunen T, Kerola T. Helicobacter pylori- associated gastritis. Evolution of histologic changes over 10 years. Scand J Gastroenterol 1995;30: 542–9.
   Google Scholar
• Villako K, Kerri M, Maaroos HI, Sipponen P, Tammur R, Tamm A, et al. A 12-year follow-up study of chronic gastritis and Helicobacter pylori in a population-based random sample. Scand J Gastroenterol 1995;30:964–7.
   PubMed Web of Science ®Google Scholar
• Valle J, Kekki M, Sipponen P, Ihamäki T, Siurala M. Long-term course and consequence of Helicobacter pylori gastritis. Results of a 32-year follow-up study. Scand J Gastroenterol 1996; 31: 546–50.
   Google Scholar
• El-Omar E, Penman I, Cruikshank G, Dover S, Banerjee S, Williams C, et al. Low prevalence of Helicobacter pylori in inflammatory bowel disease. Association with sulphasalazine. Gut 1994;35: 1385–8.
   Google Scholar
• Parente F, Molteni P, Bollani S, Maconi G, Vago L, Duca PG, et al. Prevalence of Helicobacter pylori infection and related upper gastrointestinal lesions in patients with inflammatory bowel diseases. A cross-sectional study with matching. Scand J Gastroenterol 1997;32:1140–6.
   PubMed Web of Science ®Google Scholar
• Taha AS, Sturrock RD, Russel RI. Helicobacter pylori and peptic ulcers in rheumatoid arthritis patients receiving gold, sulfasalazine, and nonsteroidal anti-inflammatory drugs. Am J Gastroenterol 1992;87: 1732–5.
   Google Scholar
• Janssen M, Dijkmans BA, Vandenbroucke JP, van Duijn W, Pena AS, Lamers CB. Decreased level of antibodies against Helicobacter pylori in patients with rheumatoid arthritis receiving intramuscular gold. Ann Rheum Dis 1992;51:1036–8.
   Google Scholar
• Caselli M, Pazzi P, LaCorte R, Aleotti A, Trevisani L, Stabellini G. Campylobacter-like organisms, non-steroidal anti-inflammatory drugs and gastric lesions in patients with rheumatoid arthritis. Digestion 1989;44:101–4.
   PubMed Web of Science ®Google Scholar
• Satoh K, Kimura K, Takimoto T, Kihira K. A follow-up study of atrophic gastritis and intestinal metaplasia after eradication of Helicobacter pylori. Helicobacter 1998;3:236–40.
   PubMed Web of Science ®Google Scholar
• Annibale B, Aprile MR, D’Ambra G, Caruana P, Bordi C, Delle Fave G. Cure of Helicobacter pylori infection in atrophic body gastritis patients does not improve mucosal atrophy but reduces hypergastrinemia and its related effects on body ECL-cell hyperplasia. Aliment Pharmacol Ther 2000;14:380–6.
   Google Scholar
• Sung JJ, Lin SR, Ching JY, Zhou LY, To KF, Wang RT, et al. Atrophy and intestinal metaplasia one year after cure ofH. pylori infection: a prospective, randomized study. Gastroenterology 2000;119: 7–14.
   Google Scholar
• Tucci A, Biasco G, Paparo GF. Effect of eradication of Helicobacter pylori in patients with fundic atrophic gastritis. N Engl J Med 1997;336:957–8.
   Google Scholar
• Ohkusa T, Fujiki K, Takashimizu I, Kumagai J, Tanizawa T, Eishi Y, et al. Improvement in atrophic gastritis and intestinal metaplasia in patients in whom Helicobacter pylori was eradicated. Ann Intern Med 2001;134:380–6.
   PubMed Web of Science ®Google Scholar
• Kokkola A, Sipponen P, Rautelin H, Harkonen M, Kosunen TU, Haapiainen R, et al. The effect of Helicobacter pylori eradication on the natural course of atrophic gastritis with dysplasia. Aliment Pharmacol Ther 2002;16:515–20.
   PubMed Web of Science ®Google Scholar
• Ito M, Haruma K, Kamada T, Mihara M, Kim S, Kitadai Y, et al. Helicobacter pylori eradication therapy improves atrophic gastritis and intestinal metaplasia: a 5-year prospective study of patients with atrophic gastritis. Aliment Pharmacol Ther 2002; 16:1449–56.
   PubMed Web of Science ®Google Scholar
• Zentilin P, Savarino V, Garnero A, Accardo S, Seriolo B. Is Helicobacter pylori infection a risk factor for disease severity in rheumatoid arthritis [Letter]? Gastroenterology 1999;116:503–4.
   Google Scholar
• Zentilin P, Seriolo B, Dulbecco P, Caratto E, Iiritano E, Fasciolo D, et al. Eradication of Helicobacter pylori may reduce disease severity in rheumatoid arthritis. Aliment Pharmacol Ther 2002; 16:1291–9.
   PubMed Web of Science ®Google Scholar
• McConkey B, Situnayake RD. Effects of rifampicin with and without isoniazid in rheumatoid arthritis. J Rheumatol 1988; 15: 46–50.
   PubMed Web of Science ®Google Scholar
• Tilley BC, Alarcon GS, Heyse SP, Trentham DE, Neuner R, Kaplan DA, et al. Minocycline in rheumatoid arthritis. A 48- week, double blind, placebo-controlled trial. Ann Intern Med 1995;122: 81–9.
   Google Scholar